Abstract: Described herein are antimicrobial copolymers comprising (i) a polymer backbone and a plurality of thiouronium groups covalently bonded to the polymer backbone and (ii) a plurality of quaternary ammonium groups covalently bonded to the polymer backbone. Also described herein are methods for making the copolymers described herein and their use in disinfecting compositions.

Abstract: The invention provides a method of treating FX syndrome and FX premutation by administering an effective amount of a ?-opioid receptor antagonist to an individual having FX syndrome or FX premutation.

Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.

Abstract: A space efficient photo-bioreactor. The bioreactor grows microalgae in a tall array of transparent flooded tubes. A nutrient media is circulated through the tubes. The array is configured to maximize the amount of sunlight falling upon each tube so that growth of the microalgae is as uniform as possible. A vertically-oriented gasser tube is provided. Gas is injected into this gasser tube along with the liquid nutrient medium. A bubble-size limiter is employed in the gas injector. The flow rates are configured so that the liquid nutrient medium and injected gas remain within the vertical gasser tube for 30 seconds or more.

Abstract: A method of making a 2-halonicotinonitrile comprises reacting an alkylidene nitrile with a C1-compound in an organic solvent and a dehydrating agent. The dehydrating agent substantially retards dimerization of the alkylidene nitrile during the reaction. The enamine intermediate that forms from the reaction is cyclized using a halide donor to make the 2-halonicotinonitrile.

Abstract: The present disclosure provides FGF1 mutant proteins having one or more mutations in the heparin binding domain. Such mutants may also have an N-terminal deletion, point mutation(s), or combinations thereof. In some examples, the mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.

Abstract: Described is a method of administering nor-binaltorphimine (nor-BNI) or a nor-BNI analog to an individual having Attention Deficit/Hyperactivity Disorder (ADHD) to thereby reduce the effects of ADHD in the individual.

Abstract: The ?-trefoil protein human fibroblast growth factor-1 (FGF-1) is made up of a six-stranded anti-parallel ?-barrel closed off on one end by three ?-hairpins, thus exhibiting a three-fold axis of structural symmetry. The N- and C-termini ?-strands hydrogen bond to each other and are postulated from both NMR and X-ray structure data to represent a structurally-weakened region of the ?-barrel. Val mutations within the N- and C-termini ?-strands are shown to stabilize the structure and to increase van der Waals contacts by filling local cavities present within this region. Mutations that increase van der Waals contacts between both the N- and C-termini ?-strands are generally associated with significant reductions in the unfolding kinetics, and also increase the cooperativity of unfolding. Surprisingly, several mutant polypeptides herein disclosed greatly exceed the wild-type polypeptide in ability to stimulate human fibroblasts to proliferate.